Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RECALL-VAX RV01
- Development stage
- Discontinued
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
RECALL-VAX RV01 (RV01) is a preclinical active therapeutic vaccine candidate developed by Intellect Neurosciences for the treatment and prevention of Alzheimer's disease and other neurological disorders. Derived from the company's proprietary RECALL-VAX platform, RV01 is a chimeric peptide vaccine designed to generate a highly specific immune response against beta amyloid. The vaccine construct consists of a short human beta-amyloid B-cell neoepitope linked to a bacterial T-cell epitope, such as tetanus toxoid, to trigger robust antibody production without causing harmful autoimmune inflammation. Development of RV01, along with its sibling candidates RV02 (targeting delta tau) and RV03 (targeting both beta amyloid and delta tau), has been discontinued as Intellect Neurosciences is defunct.
- Other names
- RECALL-VAXRECALL-VAX (RV01)
02
Targets
Aβ (Amyloid-beta peptides and aggregates)TT (Tetanus toxoid)
Beyond the preview
Go deeper on RECALL-VAX RV01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RECALL-VAX RV01.